Innovative platform technology to identify novel tumor targets and generate first-in-class antibodies.

Eximmium is a biotechnology company in Munich, Germany, and Singapore.

The company was founded in April 2021 as a spin-off from Helmholtz Munich and aims at the identification of new targets and the development of first-in-class antibodies to revolutionize treatment options and companion diagnostics for cancer patients.